Showing results (851-860 of 1,163) with videos related to

Sort By:
Pageof 117
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 27, 2015
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signalingYulyana Yulyana, Ivy A W Ho, Kian Chuan Sia, et al.
International Journal of Molecular Sciences|November 13, 2021
Ventricular TLR4 Levels Abrogate TLR2-Mediated Adverse Cardiac Remodeling upon Pressure Overload in MiceElise L Kessler, Jiong-Wei Wang, Bart Kok, et al.
The Journal of Clinical Endocrinology and Metabolism|August 19, 2011
Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studiesAbigail May Khan, Susan Cheng, Martin Magnusson, et al.
ESC Heart Failure|April 7, 2022
Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fractionGianluigi Savarese, Alicia Uijl, Wouter Ouwerkerk, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
The American Journal of Cardiology|October 27, 2019
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)Thomas C Hanff, David M Kaye, Christopher S Hayward, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
JACC. Advances|July 30, 2024
Interleukin-6 and Cardiovascular Events in Healthy Adults: MESAMuhammad Shahzeb Khan, Khawaja M Talha, Muhammad Haisum Maqsood, et al.
JACC. Asia|December 14, 2023
Clinical Features of Heart Failure With Normal Ejection Fraction: Insights From the ASIAN-HF RegistryKanako Teramoto, Wouter Ouwerkerk, Wan Ting Tay, et al.
Pageof 117